NextPharma Technologies Engages Services of Ron Collins, Principal of Goldman-Collins Associates as it Expands its US and Canadian Presence
Surrey, UK, 20th August 2009
Surrey, UK, 20th August, 2009 - NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries is pleased to announce that it has engaged the services of Ron Collins, to represent NextPharma’s business development affairs in the Eastern part of the United States and Canada in response to increased demand for NextPharma contract outsourcing services.
Sean Marett, Managing Director NextPharma Technologies, Product Development Services, commented: “We are delighted to have Ron working with us - he has a proven track record and extensive knowledge of the North American and Canadian pharmaceutical and biotechnology markets. I am convinced that he will make a significant contribution to NextPharma’s expanding presence in the United States and Canada as we continue to enhance our world class product development, contract manufacturing and logistics services globally”.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing, with particular expertise in pharmaceutical development and manufacture of oncology medicines.
NextPharma’s North American operation based in San Diego, California, serves small to large corporations world wide in the biotechnology, pharmaceutical, diagnostic, and medical device industries. Its aseptic area has multiple clean room suites offering Class 10,000 (Class 7 or Class C) formulation rooms and Class 100 (Class 5 or Class A) filling hoods or rooms. This facility is FDA licensed for drugs and medical devices and ISO 13485:2003 certified for medical device manufacturing.
Contact:
Bill Wedlake
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel +44 (0) 1483 479 121
Kathleen J. Primes
VP, Operations
NextPharma Technologies Inc.
Tel. +1 858 450 3123
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industries. We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing.
We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture.
We operate globally with seven product development centers, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.
We have 1,200 employees dedicated to serving over 200 customers world wide and a
customer base, which includes many of the world’s leading pharmaceutical, specialty pharmaceutical and biotechnology companies.
We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.
About Goldman-Collins Associates
Goldman-Collins Associates is an International Business Consulting company formed in 1999. It specializes in mergers, acquisitions, business development, company start-ups, and business planning and analysis. Since June 2000, Goldman-Collins Associates has been responsible for starting two domestic companies and one international company; and has obtained major funding and managed a major expansion for a biotechnology company.
Ron Collins, a scientist by training, served as a Vice President of the Polaroid Corporation and later as President and CEO of Transtec Manufacturing Systems.
In 1999, Ron established Goldman-Collins Associates as international consultants to high technology industries. For the past four years Ron has focused exclusively on the biotechnology and pharmaceutical industry.